Purpose Development of a gallium-68-labeled renal tracer can be a good substitute for Tc-99m, a known SPECT tracer. In this study, effort was made to develop 6 8 Gaethylenecysteamine cysteine ( 68 Ga-ECC). Methods Ga-ECC was prepared using generator-based 68 GaCl 3 and ethylenecysteamine cysteine (ECC) at optimized conditions. Stability of the complex was checked in human serum followed by partition coefficient determination of the tracer. The biodistribution of the tracer in rats was studied using tissue counting and PET/CT imaging up to 120 min. Results Ga-ECC was prepared at optimized conditions in 15 min at 90°C (radiochemical purity ≈97±0.88 % ITLC, >99 % HPLC, specific activity: 210±5 GBq/mM).
Introduction
The interesting physical properties and availability of gallium-68 as a generator make it an interesting nuclide for developing new PET tracers [1] . The increasing trend in the production and use of PET radionuclides in nuclear medicine has offered new opportunities for researchers to focus on the production of new Ga-68 radiopharmaceuticals because of the availability and commercialization of Ge-68/Ga-68 generators.
Germanium-68 decays by pure electron capture (EC) to the ground state of 68 Ga with a half-life of 270.95 days [2] . Gallium-68 in turn decays with a half-life of 67.71 (9) min by a combination of EC and positron emission primarily to the ground state of 68 Zn, but also with a branch to an excited state at 1,077 keV with a probability of about 3 % and a number of higher excited states with a combined probability of under 0.4 %. However, not many Ga-68 tracers have been developed for various diseases excluding peptides for oncological studies. In one study, the application of Ga-88 NOTA chelate was reported as a possible renal agent [3] .
Preparation and biodistribution of 67 Ga-N,N'-ethylene-di-L-cysteine ( 67 Ga-EC) [4] have been reported previously [5] , but most of the activity was accumulated in the liver, which limited its further applications. On the other hand, the monocarboxylic derivative of EC, i.e., ECC, has only been reported as 99m Tc complex [6] used in renal imaging. Recently, Ga-67-labeled ethylenecysteamine cysteine ( 67 Ga-ECC) has been reported [7] as a surrogate for developing a related Ga-68 complex. However, the assessment of the induced irradiation dose to human patients based on Ga-67 complex could impose the highest absorbed doses in the spleen and liver with 33.766 and 16.847 mGy, respectively [8] , which in part can be due to Ga-67 rather than a long half life. Developing a homolog 68 Ga tracer not only provides the advantages of a PET tracer from the imaging point of view, but also a presents the possibility of in-clinic production of the tracer using an available Ga-68 generator. In this study, we report the development and preclinical evaluation of a new 68 Ga-ECC complex demonstrating significant urinary excretion such as that of the homolog Tc-99m compound for urinary system PET applications (Fig. 1) .
Experimental
The 68 Ge/ 68 Ga generator (50 mCi/day activity) was obtained from Pars Isotope Co., Karaj, Iran. Chemicals were purchased from the Aldrich Chemical Co. (Germany). The ECC diastromer used in this study was L,L-ethylenedicysteine, which is locally available in the country from Pars Isotope Co., Tehran, Iran, with the request to remove SnCl 2 from the formulation, which was produced according to the company's published procedure [9] . Thin-layer chromatography (TLC) for ECC quality control was performed on polymer-backed silica gel, F 1500/LS 254, 20× 20 cm, TLC Ready Foil, Schleicher & Schuell®, Germany. Normal saline and sodium acetate used for radiolabeling were of high purity and had been filtered through 0.22-μm Cativex filters. Analytical high-performance liquid chromatography (HPLC), used to determine the specific activity, was performed by a Shimadzu LC-10AT, armed with two detector systems, a flow scintillation analyzer (Packard-150 TR) and UV visible (Shimadzu) using the Whatman Partisphere C-18 250×4.6-mm column, Whatman, NJ (USA). Analytical HPLC was also used to determine the specific radioactivity of the labeled compound. A standard curve was generated to calculate the mass of the final solution. Instant thin-layer chromatography (ITLC) was performed by counting Whatman no. 2 papers using a thin-layer chromatography scanner, Bioscan AR2000, Bioscan Europe Ltd. (France). Biodistribution data were acquired by counting normal saline-washed tissues after weighing on a Canberra™ high-purity germanium (HPGe) detector (model GC1020-7500SL). Radionuclidic purity was checked with the same detector. For activity measurement of the samples, a CRC Capintech Radiometer (NJ, USA) was used. All calculations and ITLC counting were based on the 511-keV peak. Animal studies were performed in accordance with the UK Biological Council's Guidelines on the Use of Living Animals in Scientific Investigations, 2nd edn.
68
Ge/ 68 Ga Generator A prototype 50-mCi 68 Ge/ 68 Ga generator, developed at Pars Isotope Co., Iran, was used in this study. Briefly, metallic gallium powder was melted and transferred in niobium capsules and sure sealed. The target was irradiated at 29-MeV energy in a 30-MeV IBA cyclotron (effective 22-MeV protons on the target material). After irradiation the target material was dissolved in 12 M H 2 SO 4 while being gently heated and stirred. To increase the solubility, 30 % hydrogen peroxide was added to the mixture followed by the addition of 2 M HCl (30 ml). After completion of the dissolution, carbon tetrachloride (150 ml) was added to the mixture, and the organic layer containing 68 Ge was extracted from 68 Ga containing aqueous solution.
Ge was then back-extracted into aqueous solution using 0.05 M HCl. The final solution was then used in the manufacture of a SnO 2 -based generator.
Quality Control of the Product
Control of Radionuclide Purity Gamma spectroscopy of the final sample was carried out counting in an HPGe detector coupled to a Canberra™ multichannel analyzer for 1,000 s. Breakthrough was measured by counting the same sample 48 h after the first test for the detection of a small amount of Ge-68 in the sample.
Chemical Purity Control This step was carried out to ensure that the amounts of Sn, Fe and copper ions resulting from the target material and backing in the final product were acceptable regarding the internationally accepted limits. Chemical purity was checked by the ICP-OES method. The detection limit of our system was 0.1 ppm for both zinc and copper ions.
Radiochemical Purity Control In order to determine the radiochemical purity of the eluted Ga-68 activity, ITLC chromatograms of 6 8 GaCl 3 solution in 10 % ammonium acetate:methanol on Silicagel sheets and in 10 mM DTPA solution (pH∼4) on Whatman no. 1 paper were performed to check the percentage of the colloidal Ga-68 fraction and/ or non-cationic gallium species. 68 Ga-ECC The acidic solution (100 μl) of 68 GaCl 3 (2.5 mCi) was transferred to a 5-ml borosilicate vial Ga-ECC complex and heated to dryness using a flow of N 2 gas at 50-60°C followed by the addition of ammonium acetate solution (200 μl, 0.5 M). Then 250 μl of ECC dissolved in 0.1 M acetate buffer, pH=5 (1 mg/ml, 1 μmole of ECC), was added to the gallium-containing vial, vortexed at 90°C for 10-30 min and controlled for radiochemical purity. The active solution with acceptable radiochemical purity was sterile filtered using a 0.22-μm membrane, and the pH was adjusted to 5.5-7.
Preparation of
Quality Control of 68 Ga-ECC Radio Thin-Layer Chromatography A 5-μl sample of the final fraction was spotted on Whatman no. 2 paper, and a 0.4 M sodium acetate:methanol (7:3) mixture was used as the mobile phase.
High-Performance Liquid Chromatography HPLC was performed with a flow rate of 1 ml/min, pressure: 1,850 psi (130 kgF/cm 2 ) for 20 min. HPLC was performed on the final preparation using a mixture of water:acetonitrile 3:2(v/v) as the eluent by means of a reversed phase Whatman Partisphere C 18 column, 4.6×250 mm.
Determination of the Partition Coefficient
The partition coefficient (log P) of 68 Ga-ECC was calculated followed by the determination of P (P=the ratio of specific activities of the organic and aqueous phases). A mixture of 1 ml of 1-octanol and 1 ml of isotonic acetate-buffered saline (pH=7) containing approximately 3.7 MBq of the radiolabeled gallium complex at 37°C was vortexed 1 min and left for 5 min. Following centrifugation at >1,200 g for 5 min, the octanol and aqueous phases were sampled and counted in an automatic well-type counter.
A 500-μl sample of the octanol phase from this experiment was shaken again two to three times with fresh buffer samples. The reported log P values are the average of the second and third extractions from three to four independent measurements.
Stability Tests
The stability of the complex was checked according to the conventional ITLC method [10] . A sample of 68 Ga-ECC (37 MBq) was kept at room temperature for up to 2 h while being checked by ITLC at time intervals in order to check the stability in the final product using the above chromatography system.
In Vitro Stability of 68 Ga-ECC in the Presence of Human Serum The final solution (200 μCi, 50 μl) was incubated in the presence of freshly prepared human serum (300 μl) (purchased from the Iranian Blood Transfusion Organization, Tehran) and kept at 37°C for 2 h. Every 30 min, trichloroacetic acid (10 %, 100 μl) was added to a portion of the mixture (50 μl), and the mixture was centrifuged at 3,000 rpm for 5 min followed by decanting the supernatant from the debris. The stability was determined by performing frequent ITLC analysis of the supernatant using the above-mentioned ITLC system.
Biodistribution in Wild-Type Rats
The distribution of the radiolabeled complex as well as free Ga-68 cations among tissues was determined in rats. The total amount of radioactivity injected into each rat was measured by counting the 1-ml syringe before and after injection in a dose calibrator with fixed geometry.
The animals were killed by CO 2 asphyxiation at selected times after injection (n=3 for each time interval), the tissues (blood, heart, lung, brain, intestine, feces, skin, stomach, kidneys, liver, muscle and bone) were weighed and rinsed with Imaging Studies PET/CT imaging was performed with a PET/CT scanner (Biograph 6 TrueX; Siemens Medical Solutions). The rats were placed in a supine position. Static PET images were acquired for 10 min with three sets of emission images starting 30, 60 and 90 min after [
68 Ga]ECC injection in the rats. In addition, PET emission scans were preceded by CT scans performed for anatomical reference and attenuation correction (spatial resolution 1.25 mm, 80 kV, 150 mAs) with a total CT scanning time of 20 s. Reconstruction was performed using the iterative algorithm with attenuation correction. The reconstruction settings were 4 iterations and 21 subsets to a 256×256 matrix, with a post filtering of 2 mm. Transmission data were reconstructed into a matrix of equal size by means of filtered back-projection, yielding a coregistered image set. The reconstructed emission images were reformatted into coronal, sagittal and maximum intensity projection (MIP) image sets.
Results and Discussion
Fritzberg and coworkers [11] Tc-ethylenedicysteine ( 99m Tc-EC) was proposed as a new renal radiopharmaceutical. The mentioned renal tracer agents have a carbonyl glycine (-CO-N-CH 2 -COOH) sequence in their structure, which is assumed to be of great importance for an efficient interaction of the compound with the renal tubular transport proteins [12] . Tc-EC, however, is the only one of these agents that has two carboxylate functions. To study whether the two carboxylates of 99m Tc-EC are essential for the efficient renal handling of this compound, ( 99m Tc-ECC) was synthesized and evaluated.
Regarding the reported structure-activity relationship, it was shown that the modifications in the central metal core were not of great importance for the renal protein interaction to demonstrate the renal imaging activity while increasing the stability of In and Ga complexes; thus, introduction of radiogallium seemed feasible in the development of possible new tracers. The development of the Ga-68 seemed interesting for PET studies.
Development and Quality Control of the 68 
Ga Generator
Radiochemical separation of Ge-68 from irradiated natural Ga was performed by a two-step extraction in an organic solution followed by back extraction with 96 % yield. The presence and absence of 68 Ga and 68 Ge were checked at each step using an HPGe detector (Fig. 2) . Radionuclidic control showed the presence of 511 and 1077 keV, all originating from 68 Ga, and showed a radionuclidic purity higher than 99 % (E.O.S.).
For the quality control of the 68 GaCl 3 solution, a timeactivity study was performed at the eluted sample after >>10 half-lives of the The concentrations of tin (from generator material), iron (from the sealing parts and acid impurities), zinc (as a decay product) and gallium (as the target material) were determined using the inductively coupled plasma (ICP-OES) method (Table 1.). The results showed that during the development of Generator types 1-3 better chemical purities for all impurities were obtained; however, the results are not very significant. As a radiolabeling source for Ga-68-based radiopharmaceuticals, especially ligands with very low molarities (including peptides), this chemical purity is crucial, and usually this chemical purity suffices for the procedure.
One important issue in the eluted activity was the determination of Ga-68 in radiochemical form. In highly acidic DTPA aq. solution (solvent 1), free 68 
Ga
3+ is coordinated to a more lipophilic moiety as 68 Ga (DTPA) 2-and migrates to a higher R f. (Fig. 3) . The small radioactive fraction remaining at the origin could be associated to colloids, since in the presence of a very strong complexing agent (i.e., DTPA), the existence of other ionic species than 68 Ga(DTPA) 2-is rare. On the other hand, a 10 % ammonium acetate:methanol mixture (1:1) (solvent 2) was also used for the determination of radiochemical purity.
The fast eluting species was possibly 68 Ga, and other ionic forms of Ga-68 such as 68 GaCl 4 -(if it existed) remained at the origin (R f .0) as well as colloids (not detected) (Fig. 3) .
The differences in the impurity peaks in the two chromatograms could be in part related to the presence of a colloidal impurity, which was insignificant. Also an insignificant (about <1 %) amount of activity could be attributed to other ionic impurities.
Radiolabeling Because of the engagement of several polar functional groups in its structure, radiolabeling of ECC with gallium cation affects its chromatographic properties, and the final complex is more lipophilic. The free gallium remains at the origin of the paper as a single peak in ITLC studies (Figs. 2,  3 and 4) .
Regarding the purification step for obtaining higher radiochemical purity for the tracer (>97 %), in our hands we were not able to remove the free Ga-68 cation from the final solution using common SPE methods. Due to the ionic nature of the complex (although it was more lipophilic than free 68 Ga), small column Si and/or C 18 purification tests were not successful. On the other hand, in order to develop a kit formulation model for this tracer as for 99m Tc-radiopharmaceuticals, we did not continue the purification step, since there are no purification steps in the kit formulations.
According to many pharmacopoeias, a tracer is acceptable for injecting >90 % of radiochemical purity, and this is mostly true for many clinically prepared 99m Tc-radiopharmaceuticals. At room temperature, no detectable complex was formed. The best temperature was found to be 85-90°C. At this temperature, when the freshly milked gallium-68 fraction with the highest specific activity was used, all the radiogallium was inserted into the complex. Although in the reported method of 67 
Ga-EC and 99m
Tc-ECC preparation, the complexes were formed at room temperature, the radiolabeling reaction for Fig. 6 Percentage of the injected dose per gram (% ID/g) of 68 Ga cation in mouse tissues at 30-120 min post-injection Fig. 7 Biodistribution of 68 Ga-ECC (37 MBq, 100 μCi) in wild-type rats 15-120 min after iv injection via the tail vein (%ID/g: percentage of the injected dose per gram of tissue calculated based on the area under the curve of the 511-keV peak in the gamma spectrum) (n=5) Ga-ECC at 15-120 min 68 Ga-ECC was completed by heating. The final radiolabeled complex in aqueous media was ready-to-inject solution.
Although the ITLC studies approved the production of the radiolabeled compound, HPLC studies demonstrated the existence of radiolabeled species using both UVand scintillation detectors. A more late-eluting compound at 5.85 min (scintillation detector) related to the 5.75-min peak (UV detector; not shown) demonstrated the presence of a rather hydrophilic complex related to 68 Ga-ECC, while free 68 Ga cation eluted at 3.54 min (scintillation detector) was not observed in the radiolabeled sample (Fig. 5) .
Optimization studies for time, pH and temperature were performed to obtain a short-time radiolabeling procedure because of the short-half life of 68 Ga. The solution was stable at room temperature up to 2 h post-formulation, allowing performance of biological experiments.
Partition Coefficient of [ 68

Ga]-ECC
As expected from the chemical formula in Fig. 1 , the lipophilicity of the 68 Ga-ECC compound was rather water soluble because of the ionic nature of the radiocomplex. The measured octanol/water partition coefficient, P, for the complex was found to depend on the pH of the solution. At pH 7, the logP was -1.378. The water solubility of the radiocomplex leads to less unnecessary uptake in tissues, including the liver and fat, and faster kidney washout.
Stability
The chemical stability of 68 Ga-ECC was high enough to perform further studies. Incubation of 68 Ga-ECC in freshly prepared human serum for 2 h at 37°C showed no loss of 68 Ga from the complex. The radiochemical purity of the complex remained >95 % for 2 h under physiologic conditions.
Biodistribution
Biodistribution studies were performed for 68 Ga-ECC and free Ga 3+ . The %ID/g data for free Ga 3+ are summarized in Fig. 6 . As reported previously, 68 Ga is majorly excreted from the gastrointestinal tract (GIT) with high blood contents because of the transferrin binding at early time intervals; also a significant colon, bone and stomach activity content is observed. The kidney is not a significant accumulation site.
In case of 68 Ga-ECC, the tracer accumulated in the liver very slightly, while 67 Ga-EC has been reported to be retained in the liver, suggesting the instability of the complex in vivo. 68 Ga-ECC has been reported to be stable in rat plasma in vivo at 2 h post-injection [3] . In case of 68 Ga-ECC, however, we observed different uptake results; as shown in Fig. 7 , the complex is significantly excreted from kidneys, and very low amounts of activity are observed in the liver.
Thus, 68 Ga-ECC is majorly excreted from the urinary tract (more than 50 % in 30 min) as shown for the homologous Tc99m compound [13] . Accumulation of 68 Ga-EC in the liver, which can be a result of complex degradation and release of free Ga, is almost not detected. The ionic nature of the complex, however, would limit the penetration into the bloodbrain barrier, as shown in Fig. 7 .
The tracer is rapidly washed away from the blood while the excretion takes place via kidneys. The other organ uptakes are not significant at all time intervals. The major activity is observed in the bladder, which demonstrates the kidney uptake started less than 15 min after the injection.
The biodistribution of 99m Tc-EC has been reported previously [14] ; also, the biodistribution of 99m Tc-ECC has been reported for all diastereoisomers as well as Tc-L,L-ECC [5] . Table 2 demonstrates the biodistribution of two formerly  developed   99m   Tc tracers and   68 Ga-ECC 30 min post injection. 68 Ga-ECC demonstrates higher blood retention in comparison to two other Tc-99m tracers, which can be a sign of higher protein binding. While the liver retention of the tracer is very similar to 99m Tc-tracers, suggesting a suitable property for the tracer with a not much higher imposed liver dose, the physical half life is also 5-6 times less than that of Tc-99m. On the Ga-ECC (3 %) is far higher than that of two other tracers (0.68 and 0.8 %), suggesting a significant binding mechanism to renal tubes as well as better kidney imaging properties. Figure 8 demonstrates the target (kidney) to non-target ratios for 68 Ga-ECC at various time intervals, excluding 60-min activity ratios for bone; the highest target:non-target ratios are demonstrated in 15 min (or maybe less); almost all ratios are significant.
The reduction of blood and kidney-specific activities is an exponential function of time, as shown in Figs. 9 and 10. These data demonstrate the specific and rapid washout of the tracer through the kidneys, as observed for other anionic renal imaging agents.
PET/CT Imaging of 68 
Ga-ECC in Rats
As shown in Fig. 11 , the only visible organs were the liver, kidneys and bladder. There was a significant uptake of 68 Ga-ECC in kidneys with low levels of accumulation in other organs. For quantitative uptake behavior, maximum standard uptake value (SUV max ) ratios were calculated for the liver to kidney in all imaging studies.
In Fig. 12a , the first rat, the SUV max ratios of the liver to left kidney were 0.38 and 0.39 for 30 and 90 min time frames, respectively, indicating the high kidney uptake. The activity concentration in the left kidney was more pronounced than in the right one (SUV max of 2.3 vs. 1.99 and SUV max of 2.1 vs. 2.03 for 30 min and 90 min, respectively).
In Fig. (12b) , the second rat, the SUV max ratios of the liver to kidneys were 0.39 and 0.41 for left and right kidneys, respectively. Again, the activity concentration in the left kidney was more pronounced than in the right one (SUV max of 3.83 vs. 3.61).
Conclusion
Total radiolabeling and formulation of 68 Ga-ECC took about 30 min, with a radiochemical purity (>97 ±0.8 % ITLC, >99 % HPLC) and specific activity of 210±5 GBq/mmol. No other radiolabeled by-products were observed by ITLC analysis of the final preparations. The radio-radiolabeled complex was stable in aqueous solution and in human serum at 37°C for at least 2 h. The partition coefficient of the tracer was determined in an octanol:saline mixture (log P. −1.378), demonstrating a water-soluble complex was formed. Biodistribution of the complex in wild-type rats demonstrated significant kidney uptake in 15 min with 87 % excretion in 2 h through urinary excretion. The SUV max ratios of the liver to left kidney were 0.38 and 0.39 for 30-and 90-min time frames, respectively, indicating the high kidney uptake. The activity concentration in the left kidney was more pronounced than in the right one (SUV max of 2.3 vs. 1.99 and SUV max of 2.1 vs. 2.03 for 30 min and 90 min, respectively). It is suggested that 68 Ga-ECC could be a possible PET tracer considering that the fast kidney uptake and short half life of gallium-68 suggest a good candidate for imaging application of [ 68 Ga]-PET studies.
